Plain-English translation of NCT06762873 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a neuromodulation therapy called Trans-Q DISE to treat obstructive sleep apnea (OSA)—a common condition where people stop breathing repeatedly during sleep. Researchers want to understand how this new treatment works specifically in Latin American patients and whether it can reduce breathing interruptions. The study will examine the structure of the upper airway and measure how well the treatment helps people breathe better at night.
Obstructive sleep apnea affects many people, but current treatment options (like CPAP masks) don't work well for everyone. This trial aims to see whether this new nerve-stimulation approach could be a better alternative for patients who can't access or tolerate other treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will undergo a procedure to receive the neuromodulation device and then be monitored to see how well it works for you. You'll have sleep studies (polysomnography) to measure your breathing patterns before and after treatment. Throughout the study, you'll work with the research team to track how the device affects your sleep quality and daytime alertness. The exact timeline and number of visits will be discussed with you when you enroll.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Paraguay
Phase
Safety & dosing
Sponsor
Lunair Medical
Enrollment target
~50 participants
Started
November 2024
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andrea Director of Clinical Operations
Lunair Medical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.